Brief: Metavia Announces Positive Top-Line Results From Its Phase 2A Clinical Trial Of Da-1241 In Patients With Presumed MASH

MetaVia

18/12/2024 13:36

Dec 18 (Reuters) - MetaVia Inc  MTVA.O :
    * METAVIA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS PHASE
2A
CLINICAL TRIAL OF DA-1241 IN PATIENTS WITH PRESUMED MASH
    * DA-1241 VERY WELL TOLERATED WITH NO DRUG-RELATED SERIOUS
ADVERSE
EVENTS
    * DA-1241 SHOWS SIGNIFICANT REDUCTION IN ALT LEVELS AT WEEKS
4 AND
8
    * DA-1241 100MG SHOWS SIGNIFICANT IMPROVEMENTS IN CAP SCORE
AT
WEEK 16
    * DA-1241 100MG SHOWS SIGNIFICANT REDUCTIONS IN HBA1C AT
WEEK 16
    * EXPECTS END OF PHASE 2 MEETING WITH FDA IN FIRST HALF OF
2025

Source text:  ID:nPn4R0BS7a 
Further company coverage:  MTVA.O 

 ((Reuters.Briefs@thomsonreuters.com;))